Higher Serum Angiopoietin 2 Levels Are Independently Associated With Coronary Microvascular Dysfunction in Patients With Angina in the Absence of Obstructive Coronary Artery Disease
If you’ve ever had chest pain that feels like classic angina—pressure under the sternum, triggered by activity or stress, relieved by rest—but your coronary angiogram shows no blockages, you’re not alone. Up to 30% of people with angina have no obstructive coronary artery disease (CAD)—meaning their main heart arteries are clear. For many, the real culprit is coronary microvascular dysfunction (CMD): damage to the tiny blood vessels that supply the heart muscle, which can’t be seen on standard angiograms. But how do we identify CMD early? A 2020 study from researchers at Peking University Third Hospital and Beijing First Hospital of Integrated Chinese and Western Medicine suggests a new clue: higher levels of a protein called angiopoietin-2 (Ang-2) in the blood may be linked to CMD in these patients.
What Is Angiopoietin-2, and Why Does It Matter?
Ang-2 is a protein made by the lining of blood vessels (endothelial cells). It plays a key role in angiogenesis (forming new blood vessels) and vascular remodeling (changing vessel structure). Normally, Ang-2 balances another protein, Ang-1, to keep blood vessels stable. But when the heart is low on oxygen (ischemia)—like in CAD or CMD—Ang-2 levels rise. Previous research has shown Ang-2 is a biomarker for CAD and cardiovascular risk, but no one had studied its link to CMD until this study.
How Was the Study Done?
The cross-sectional study included 125 adults with typical or atypical angina (chest pain that meets 2–3 classic criteria: substernal discomfort, triggered by activity/emotion, relieved by rest/nitroglycerin) who had <50% blockage in any main coronary artery (confirmed by angiography or CT scan). Researchers excluded people with other causes of angina (e.g., valve disease, heart failure) or conditions that could affect results (e.g., kidney disease, inflammation).
To measure CMD, they used coronary flow reserve (CFR)—a test of how well small coronary vessels can increase blood flow during stress. CFR was calculated by comparing peak blood flow velocity in the distal left anterior descending artery (LAD) at rest and after infusing adenosine (a drug that dilates blood vessels). A CFR <2.5 meant impaired microvascular function.
Blood samples were tested for Ang-2 using enzyme-linked immunosorbent assay (ELISA), a standard lab technique. Researchers also collected data on age, sex, comorbidities (hypertension, diabetes), and other biomarkers (e.g., NT-pro BNP, a heart failure marker).
What Did They Find?
People with impaired CFR (CFR <2.5) had significantly higher Ang-2 levels than those with normal CFR:
- Impaired CFR: 763.3 ± 264.9 pg/mL
- Normal CFR: 579.7 ± 169.3 pg/mL
Ang-2 levels were negatively correlated with CFR—meaning higher Ang-2 meant worse microvascular function (r = -0.386, P < 0.001). Even after adjusting for age, sex, and other risk factors, Ang-2 and age were independently linked to impaired CFR:
- For every 1 pg/mL increase in Ang-2, the odds of impaired CFR rose by 0.4% (odds ratio [OR] 1.004, 95% confidence interval [CI] 1.001–1.006).
- For every 1-year increase in age, the odds of impaired CFR rose by 8.8% (OR 1.088, 95% CI 1.023–1.156).
Ang-2 also predicted impaired CFR with moderate accuracy: the area under the curve (AUC) was 0.712 (95% CI 0.612–0.813). A cut-off of 648 pg/mL identified impaired CFR with 71.4% sensitivity (correctly found 71% of cases) and 67.8% specificity (correctly ruled out 68% of non-cases).
What Does This Mean for Patients and Doctors?
CMD is often called “microvascular angina” because it causes chest pain despite clear main arteries. It’s linked to worse outcomes (e.g., heart failure, death), but it’s hard to diagnose—CFR testing requires specialized equipment. This study suggests Ang-2 could be a simple blood biomarker for CMD in people with angina but no obstructive CAD.
Why does Ang-2 work? CMD is driven by two key processes:
- Endothelial dysfunction: Damaged blood vessel linings can’t dilate properly.
- Low-grade inflammation: Chronic inflammation damages small vessels.
Ang-2 is tied to both. It blocks Ang-1’s stabilizing effect, making endothelial cells more sensitive to inflammatory signals (e.g., TNF-alpha). This leads to less flexible small vessels that can’t increase blood flow when the heart needs it.
Limitations to Consider
- Cross-sectional design: The study can’t prove high Ang-2 causes CMD—only that they’re associated.
- Small sample size: Results need confirmation in larger, more diverse groups.
- Single-artery measurement: CFR was only tested in the LAD, so it may not reflect all microvascular function.
Conclusion
For people with angina but no obstructive CAD, high Ang-2 levels are independently linked to impaired coronary microvascular function. This is a promising step toward better diagnosing CMD—a condition that’s often missed but can have serious consequences. Future research should test whether Ang-2 can predict long-term outcomes (e.g., heart attacks) in people with CMD.
Original Study Citation:
Chen SM, Li D, Xing X, Li ZP. Higher serum angiopoietin 2 levels are independently associated with coronary microvascular dysfunction in patients with angina in the absence of obstructive coronary artery disease. Chinese Medical Journal 2020;133(14):1662–1668. doi: doi.org/10.1097/CM9.0000000000000812
Was this helpful?
0 / 0